In July 2025, MedChina officially unveiled the 2025 Global MedTech 100 (GMT100), an authoritative annual ranking highlighting the world’s leading medical device companies based on their 2024 fiscal year revenue. Now in its third year, the GMT100 continues to serve as a vital reference for medtech professionals, investors, and policymakers seeking a clear and comprehensive view of the global landscape.

A Truly Global Perspective

Unlike many international rankings that focus primarily on Europe and the United States, the GMT100 is designed to reflect the truly global nature of the medtech industry. Special attention has been given to the rapid growth of companies from China and the broader Asia-Pacific region, showcasing their increasing role in shaping the future of healthcare technology.

This year, 12 Chinese companies earned a place on the list, demonstrating not only their expanding market presence but also their commitment to innovation and quality. These include:

• Mindray (No. 26)

• Wego (No. 63)

• United Imaging (No. 66)

• MicroPort (No. 70)

• Shinva Medical (No. 71)

• Intco Medical (No. 75)

• Yuwell Medical (No. 86)

• Lepu Medical (No. 91)

• Giant Biogene (No. 95)

• Bloomage Biotech (No. 96)

• Snibe Diagnostic (No. 99)

• Autobio Diagnostics (No. 100)

Methodology: Transparency and Accuracy

The GMT100 ranking is based strictly on medical device-related revenue reported in annual financial disclosures released before July 1, 2025. For diversified conglomerates, only revenue from medical device operations was considered.

Key principles guiding the selection process:

• Inclusion of companies with strong in-house R&D capabilities and multiple product certifications.

• Exclusion of distributors, agencies, and companies where medical devices are not the core business.

• Alignment with China’s Medical Device Regulation for clear and consistent classification.

It is important to note that reporting timelines may vary across regions due to differing fiscal year requirements. Despite this, every effort was made to ensure data transparency and reliability.

More Than a Ranking — A Reflection of Global Trends

The GMT100 offers more than just numbers — it provides insight into where medical technology is headed. The presence of so many Asia-based companies signals a shift toward a more multipolar industry, where innovation is emerging from every corner of the world.

This ranking mirrors the convergence of clinical needs, investment momentum, and technological advancement, providing a snapshot of the sector’s health and direction.

Looking Ahead

We extend our congratulations to all the companies that made this year’s GMT100. Their achievements reflect a shared commitment to improving global healthcare through technology, research, and collaboration.

MedChina remains dedicated to supporting dialogue and discovery within the global medtech community. We invite researchers, investors, industry leaders, and regulators to explore the full ranking and join us in recognizing the leaders driving this dynamic industry forward.

MedChina, July 17, 2025